The investigation of the interaction of Ce6 with human serum albumin (HSA) is a crucial issue that involves both the following aspects: (i) HSA is the endogenous carrier of Ce6 in the blood and the formation of this complex governs its cellular uptake and biodistribution [17,18,19,20] and (ii) HSA can be used to develop biocompatible protein-based nanoplatforms for cancer theranostics [21,22,23,24,25,26]. This evidence concerns the gene ALB and cancer.